NAPROXEN AND ESOMEPRAZOLE MAGNESIUM Drug Patent Profile
✉ Email this page to a colleague
When do Naproxen And Esomeprazole Magnesium patents expire, and what generic alternatives are available?
Naproxen And Esomeprazole Magnesium is a drug marketed by Actavis Labs Fl Inc, Ajanta Pharma Ltd, Dr Reddys, Mylan, and Sciegen Pharms Inc. and is included in five NDAs.
The generic ingredient in NAPROXEN AND ESOMEPRAZOLE MAGNESIUM is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.
Summary for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 3 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in NAPROXEN AND ESOMEPRAZOLE MAGNESIUM? | NAPROXEN AND ESOMEPRAZOLE MAGNESIUM excipients list |
DailyMed Link: | NAPROXEN AND ESOMEPRAZOLE MAGNESIUM at DailyMed |
Pharmacology for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Anatomical Therapeutic Chemical (ATC) Classes for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
US Patents and Regulatory Information for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavis Labs Fl Inc | NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 204470-001 | Aug 24, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Mylan | NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 204920-001 | Jul 20, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ajanta Pharma Ltd | NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 213699-002 | Oct 6, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |